<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Cancer Urology</journal-id><journal-title-group><journal-title xml:lang="en">Cancer Urology</journal-title><trans-title-group xml:lang="ru"><trans-title>Онкоурология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-9776</issn><issn publication-format="electronic">1996-1812</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">998</article-id><article-id pub-id-type="doi">10.17650/1726-9776-2020-16-1-27-34</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. RENAL CANCER</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак почки</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Tissue synthesis of some components of the renin-angiotensin system in hypertensive patients with localized kidney cancer</article-title><trans-title-group xml:lang="ru"><trans-title>Тканевой синтез некоторых компонентов ренин-ангиотензин-альдостероновой системы у гипертензивных больных локализованным раком почки</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7764-446X</contrib-id><name-alternatives><name xml:lang="en"><surname>Osokin</surname><given-names>R. A.</given-names></name><name xml:lang="ru"><surname>Осокин</surname><given-names>Р. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>70/3 Dolomanovskiy Pereulok, Rostov-on-Don 344011</italic></p></bio><bio xml:lang="ru"><p><italic>344011 Ростов-на-Дону, переулок Доломановский, 70/3</italic></p></bio><email>romanalosokin@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2798-368X</contrib-id><name-alternatives><name xml:lang="en"><surname>Aboyan</surname><given-names>I. A.</given-names></name><name xml:lang="ru"><surname>Абоян</surname><given-names>И. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>70/3 Dolomanovskiy Pereulok, Rostov-on-Don 344011</italic></p></bio><bio xml:lang="ru"><p><italic>344011 Ростов-на-Дону, переулок Доломановский, 70/3</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7553-6550</contrib-id><name-alternatives><name xml:lang="en"><surname>Komarova</surname><given-names>E. F.</given-names></name><name xml:lang="ru"><surname>Комарова</surname><given-names>Е. Ф.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>1 Ostrovityanova St., Moscow 117997</italic></p></bio><bio xml:lang="ru"><p><italic>117997 Москва, ул. Островитянова, 1</italic></p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1397-837X</contrib-id><name-alternatives><name xml:lang="en"><surname>Maksimov</surname><given-names>A. Yu.</given-names></name><name xml:lang="ru"><surname>Максимов</surname><given-names>А. Ю.</given-names></name></name-alternatives><bio xml:lang="en"><p><italic>63, 14th line St., Rostov-on-Don 344037</italic></p></bio><bio xml:lang="ru"><p><italic>344037 Ростов-на-Дону, ул. 14-я линия, 63</italic></p></bio><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1252-8094</contrib-id><name-alternatives><name xml:lang="en"><surname>Komarova</surname><given-names>E. Yu.</given-names></name><name xml:lang="ru"><surname>Комарова</surname><given-names>Е. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>29 Nakhichevanskiy Pereulok, Rostov-on-Do</italic></p></bio><bio xml:lang="ru"><p><italic>344022 Ростов-на-Дону, переулок Нахичеванский, 29</italic></p></bio><xref ref-type="aff" rid="aff4"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Rostov-on-Don Clinical diagnostic center “Health”</institution></aff><aff><institution xml:lang="ru">МБУЗ «Клинико-диагностический центр «Здоровье» г. Ростова-на-Дону»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Rostov Research Institute of Oncology, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр онкологии» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">Rostov State Medical University, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Ростовский государственный медицинский университет» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2020-03-30" publication-format="electronic"><day>30</day><month>03</month><year>2020</year></pub-date><volume>16</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>27</fpage><lpage>34</lpage><history><date date-type="received" iso-8601-date="2019-10-15"><day>15</day><month>10</month><year>2019</year></date><date date-type="accepted" iso-8601-date="2020-01-24"><day>24</day><month>01</month><year>2020</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://oncourology.abvpress.ru/oncur/article/view/998">https://oncourology.abvpress.ru/oncur/article/view/998</self-uri><abstract xml:lang="en"><p><bold><italic>Backgr</italic></bold><bold><italic>ound.</italic></bold><bold><italic> </italic></bold><italic>In the last decade, the relationship between arterial hypertension and the risk of developing kidney cancer (KC) has been pointed out. Some studies have shown that the metabolic imbalance of the components of the renal renin-angiotensin system (RAS) is associated with the development and progression of KC.</italic></p><p><bold><italic>Objective:</italic></bold><bold><italic> </italic></bold><italic>to study the state of RAS in tumor and peritumoral tissues in patients with KC on the background of arterial hypertension. </italic></p><p><bold><italic>Materials</italic></bold><bold><italic> </italic></bold><bold><italic>and</italic></bold><bold><italic> </italic></bold><bold><italic>methods.</italic></bold><bold><italic> </italic></bold><italic>In</italic><italic> </italic><italic>patients</italic><italic> </italic><italic>with</italic><italic> </italic><italic>localized</italic><italic> </italic><italic>K</italic><italic>C</italic><italic> </italic><italic>T1N0M0</italic><italic> </italic><italic>and</italic><italic> </italic><italic>grade</italic><italic> </italic><italic>I–II</italic><italic> </italic><italic>arterial</italic><italic> </italic><italic>hypertension</italic><italic> </italic><italic>without</italic><italic> </italic><italic>special</italic><italic> </italic><italic>treatment</italic><italic> </italic><italic>(n</italic><italic> </italic><italic>= 40) in the samples of tumor, peritumoral and histologically unchanged tissue, the levels of angiotensins 1, 2, 1–7 (AT1, AT2, AT(1–7)) of angiotensin-converting enzymes (ACE, ACE2) were determined by ELISA. The comparison group consisted of patients with RC without impaired blood pressure (n = 55).</italic></p><p><bold><italic>Results. </italic></bold><italic>In patients with KC, the level of AT1 is 1.5 times higher (p &lt;0.05), and AT2 is 1.6 times higher (p &lt;0.05) in tumor tissue against the background of unchanged content in peritumoral tissue compared with histologically unchanged tissue. The level of ACE is higher than histologically unchanged tissue by 2.7 times, ACE2 – by 1.6 times (in all cases p &lt;0.05), and in peritumoral tissue it is identical in histologically unchanged tissue.</italic></p><p><italic>In</italic><italic> </italic><italic>patients</italic><italic> </italic><italic>with</italic><italic> </italic><italic>K</italic><italic>C</italic><italic> </italic><italic>and</italic><italic> </italic><italic>arterial</italic><italic> </italic><italic>hypertension,</italic><italic> </italic><italic>the</italic><italic> </italic><italic>level</italic><italic> </italic><italic>of</italic><italic> </italic><italic>A</italic><italic>T1</italic><italic> </italic><italic>and</italic><italic> </italic><italic>A</italic><italic>T2</italic><italic> </italic><italic>in</italic><italic> </italic><italic>the</italic><italic> </italic><italic>tumor</italic><italic> </italic><italic>tissue</italic><italic> </italic><italic>is</italic><italic> </italic><italic>1.8</italic><italic> </italic><italic>times</italic><italic> </italic><italic>higher</italic><italic> </italic><italic>(p</italic><italic> </italic><italic>&lt;0.05)</italic><italic> </italic><italic>and</italic><italic> </italic><italic>2.1</italic><italic> </italic><italic>times</italic><italic> </italic><italic>(p</italic><italic> </italic><italic>&lt;0.01),</italic><italic> </italic><italic>respectively</italic><italic>,</italic><italic> </italic><italic>the content of AT(1–7) is 1.6 times (p &lt;0.01). In peritumoral tissue, AT1 is 1.6 times higher (p &lt;0.01) and AT2 is 1.9 times higher (p &lt;0.05). The level of AT(1–7) in the peritumoral tissue is identical to the values in the histologically unchanged tissue. The content of ACE and ACE2 in tumor tissue is 3.6 and 2.9 times higher, respectively, and in peritumoral tissue is identical to that in tumor tissue. Correlation analysis revealed a reliable direct relationship in the studied groups for all parameters, while in the peritumoral tissue of hypertensive patients, the relationship between the average blood pressure and the RAS peptide and enzymes content had a higher tightness.</italic></p><p><bold><italic>Conclusion. </italic></bold><italic>An increase in the levels of AT1 and AT2, ACE and ACE2 in the tumor tissues and peritumoral tissue in patients with localized KC, regardless of the presence of arterial hypertension at initially higher values in hypertensive patients, was shown. The presence of arterial hypertension in patients with KC changes the metabolism of local RAS in peritumoral tissue and is associated with an increase in the correlation between changes in the components of RAS and arterial hypertension.</italic></p></abstract><trans-abstract xml:lang="ru"><p><bold><italic>Введение. </italic></bold><italic>В последнее десятилетие указывается на взаимосвязь между артериальной гипертензией и риском развития рака почки (РП). В некоторых исследованиях показано, что метаболический дисбаланс компонентов внутрипочечной ренин-ангиотензиновой системы (РАС) связан с развитием и прогрессированием РП.</italic></p><p><bold><italic>Цель</italic></bold><bold><italic> </italic></bold><bold><italic>исследования</italic></bold><bold><italic> </italic></bold><italic>– </italic><italic>изучить</italic><italic> </italic><italic>состояние</italic><italic> </italic><italic>Р</italic><italic>АС</italic><italic> </italic><italic>в опухолевой и перитуморальной тканях у больных РП на фоне артериальной гипертензии.</italic></p><p><bold><italic>Ма</italic></bold><bold><italic>териалы</italic></bold><bold><italic> и методы. </italic></bold><italic>У пациентов с локализованным РП стадии Т1</italic><italic>N</italic><italic>0</italic><italic>M</italic><italic>0 и артериальной гипертензией </italic><italic>I</italic><italic>–</italic><italic>II</italic><italic> степени (</italic><italic>n</italic><italic> </italic><italic>= 40) без специального лечения в образцах опухолевой, перитуморальной и гистологически неизмененной тканей исследовали уровни ангиотензина 1, 2, 1–7 (АТ1, АТ2, АТ(1–7)) и ангиотензинпревращающих ферментов (АПФ и АПФ2) методом иммуноферментного анализа. Группу сравнения составили больные РП без нарушения артериального давления (</italic><italic>n</italic><italic> </italic><italic>= 55).</italic></p><p><bold><italic>Резу</italic></bold><bold><italic>ль</italic></bold><bold><italic>таты.</italic></bold><bold><italic> </italic></bold><italic>У больных РП без артериальной гипертензии уровень АТ1 был выше в 1,5 раза (</italic><italic>p</italic><italic> </italic><italic>&lt;0,05), АТ2 – в 1,6 раза (</italic><italic>p</italic><italic> &lt;0,05) в опухолевой ткани на фоне неизменного содержания в перитуморальной ткани по сравнению с таковым в гистологически неизмененной ткани. Уровень АПФ в гистологически неизмененной ткани оказался выше в 2,7 раза, АПФ2 – в 1,6 раза (во всех случаях р &lt;0,05), в перитуморальной ткани идентичен таковому в гистологически неизмененной ткани.</italic></p><p><italic>У больных РП с артериальной гипертензией в опухолевой ткани уровень АТ1 был выше в 1,8 раза (</italic><italic>p</italic><italic> </italic><italic>&lt;0,05),</italic><italic> А</italic><italic>Т2 </italic><italic>– </italic><italic>в 2,1 раза (</italic><italic>p</italic><italic> </italic><italic>&lt;0,01),</italic><italic> </italic><italic>А</italic><italic>Т(1–7)</italic><italic> </italic><italic>– </italic><italic>в 1,6 раза (</italic><italic>p</italic><italic> </italic><italic>&lt;0,01).</italic><italic> </italic><italic>В перитуморальной ткани уровень АТ1 оказался выше в 1,6 раза (</italic><italic>p</italic><italic> &lt;0,01),</italic><italic> </italic><italic>А</italic><italic>Т2</italic><italic> </italic><italic>– </italic><italic>в 1,9 раза (</italic><italic>p</italic><italic> &lt;0,05).</italic><italic> </italic><italic>Уровень</italic><italic> А</italic><italic>Т(1–7)</italic><italic> </italic><italic>в перитуморальной ткани идентичен значениям в гистологически неизмененной ткани. Содержание АПФ и АПФ2 в опухолевой ткани выше в 3,6 и 2,9 раза соответственно, а в перитуморальной ткани идентично таковому в опухоли почки. Корреляционный анализ выявил достоверную прямую связь в исследуемых группах по всем параметрам. При этом в перитуморальной ткани гипертензивных больных связь среднего артериального давления с показателями содержания пептидов и ферментов РАС была наиболее сильной.</italic></p><p><bold><italic>Заключение. </italic></bold><italic>Показано повышение уровней АТ1, АТ2 и АПФ, АПФ2 в тканях опухоли почки и перитуморальной ткани у больных локализованным РП вне зависимости от наличия артериальной гипертензии при исходно более высоких значениях у гипертензивных пациентов. Наличие артериальной гипертензии у больных РП меняет метаболизм локальной РАС в перитуморальной ткани и сопряжено с усилением корреляционных взаимосвязей между изменением компонентов РАС и артериальной гипертензией.</italic></p></trans-abstract><kwd-group xml:lang="en"><kwd>localized kidney cancer</kwd><kwd>arterial hypertension</kwd><kwd>local renin-angiotensin system</kwd><kwd>angiotensin</kwd><kwd>angiotensin converting enzyme</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>локализованный рак почки</kwd><kwd>артериальная гипертензия</kwd><kwd>локальная ренин-ангиотензин-альдостероновая система</kwd><kwd>ангиотензин</kwd><kwd>ангиотензинпревращающий фермент.</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Stocks T., Van Hemelrijck M., Manjer J. et al. Blood pressure and risk of cancer incidence and mortality in the metabolic syndrome and cancer project. Hypertension. 2012;59:802-810. PMID: 22353615. DOI:10.1161/HYPERTENSIONAHA.111.189258</mixed-citation><mixed-citation xml:lang="ru">Stocks T., Van Hemelrijck M., Manjer J. et al. Blood pressure and risk of cancer incidence and mortality in the metabolic syndrome and cancer project. Hypertension 2012;59(4):802–10. DOI: 10.1161/HYPERTENSIONAHA.111.189258.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Aune D., Sen A., Vatten L.J. Hypertension and the risk of endometrial cancer: a systematic review and meta-analysis of case-control and cohort studies. Sci Rep. 2017;7:44808. PMID: 28387226. DOI: 10.1038/srep44808</mixed-citation><mixed-citation xml:lang="ru">Aune D., Sen A., Vatten L.J. Hypertension and the risk of endometrial cancer: a systematic review and meta-analysis of casecontrol and cohort studies. Sci Rep 2017;7:44808. DOI: 10.1038/srep44808.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Liang Z., Xie B., Li J. et al. Hypertension and risk of prostate cancer: a systematic review and meta-analysis. Sci Rep. 2016; 6: 31358. PMID: 27511796. DOI: 10.1038/srep31358</mixed-citation><mixed-citation xml:lang="ru">Liang Z., Xie B., Li J. et al. Hypertension and risk of prostate cancer: a systematic review and meta-analysis. Sci Rep 2016;6:31358. DOI: 10.1038/srep31358.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Hidayat K., Du X., Zou S.Y., Shi B.M. Blood pressure and kidney cancer risk: meta-analysis of prospective studies. J Hypertens. 2017;35(7):1333-1344.PMID:28157813.DOI:10.1097/HJH.0000000000001286.</mixed-citation><mixed-citation xml:lang="ru">Hidayat K., Du X., Zou S.Y., Shi B.M. Blood pressure and kidney cancer risk: meta-analysis of prospective studies. J Hypertens 2017;35(7):1333–44. DOI: 10.1097/HJH.0000000000001286.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Hunyady L., Catt K.J. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol.Endocrinol 2006; 20(5):953-70. PMID: 16141358. DOI: 10.1210/me.2004-0536</mixed-citation><mixed-citation xml:lang="ru">Hunyady L., Catt K.J. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol 2006;20(5): 953–70. DOI: 10.1210/me.2004-0536.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Lau S.T., Leung P.S. Role of the RAS in pancreatic cancer. Curr. Cancer Drug Targets. 2011; 11(4): 412- 20; PMID: 21395550</mixed-citation><mixed-citation xml:lang="ru">Lau S.T., Leung P.S. Role of the RAS in pancreatic cancer. Curr Cancer Drug Targets 2011;11(4):412–20.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Wegman-Ostrosky T., Soto-Reyes E., Vidal-Millán S. et al The renin-angiotensin system meets the hallmarks of cancer. Renin Angiotensin Aldosterone Syst. 2015; 16(2):227-33. PMID: 23934336. DOI: 10.1177/1470320313496858</mixed-citation><mixed-citation xml:lang="ru">Wegman-Ostrosky T., Soto-Reyes E., Vidal-Millán S. et al. The renin-angiotensin system meets the hallmarks of cancer. Renin Angiotensin Aldosterone Syst 2015;16(2):227–33. DOI: 10.1177/1470320313496858.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Arrieta O., Villarreal-Garza C., Vizcaíno G. et al. Association between AT1 and AT2 angiotensin II receptor expression with cell proliferation and angiogenesis in operable breast cancer. Tumour Biol 2015; 36:5627–34. PMID: 25682288. DOI: 10.1007/s13277-015-3235-3</mixed-citation><mixed-citation xml:lang="ru">Arrieta O., Villarreal-Garza C., Vizcaino G. et al. Association between AT1 and AT2 angiotensin II receptor expression with cell proliferation and angiogenesis in operable breast cancer. Tumour Biol 2015;36(7): 5627–34. DOI: 10.1007/s13277-015-3235-3.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Osokin R., Kit O.I., Komarova E. et al. Urinary excretion of components of the renin-angiotensin-aldosterone system in patients having localized renal cancer. J Clin Oncol 37, 2019, suppl; abstr e14725</mixed-citation><mixed-citation xml:lang="ru">Osokin R., Kit O.I., Komarova E. et al. Urinary excretion of components of the renin-angiotensin-aldosterone system in patients having localized renal cancer. J Clin Oncol 2019;37:abstr_e14725.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Alvarenga E.C., Fonseca M.C., Carvalho C.C. et al. Angiotensin Converting Enzyme Regulates Cell Proliferation and Migration. PLoS One. 2016 ;11(12):e0165371.PMID: 27992423. DOI:10.1371/journal.pone.0165371.</mixed-citation><mixed-citation xml:lang="ru">Alvarenga E.C., Fonseca M.C., Carvalho C.C. et al. Angiotensin converting enzyme regulates cell proliferation and migration. PLoS One 2016;11(12):e0165371. DOI: 10.1371/journal.pone.0165371.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Кит О.И., Абоян И.А., Осокин Р.А., Женило В.М., Комарова Е.Ф., Максимов А.Ю. Артериальная гипертензия и рак почки: некоторые аспекты проблемы. Уральский медицинский журнал. 2018. № 3 (158). С. 42-46. [Kit O.I., Aboyan I.A., Osokin R.A., Zhenilo V.M., Komarova E.F., Maksimov A.YU. Arterial hypertension some aspects of problem. Ural'skij medicinskij zhurnal. 2018. № 3 (158). S. 42-46.(In Russ)].</mixed-citation><mixed-citation xml:lang="ru">Кит О.И., Абоян И.А., Осокин Р.А. и др. Артериальная гипертензия и рак почки: некоторые аспекты проблемы. Уральский медицинский журнал 2018;3(158):42–6. [Kit O.I., Aboyan I.A., Osokin R.A. et al. Arterial hypertension some aspects of problem. Ural’skiy medicinskiy zhurnal = Ural Medical Journal 2018;3(158):42–6. (In Russ)].</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Sobczuk P., Szczylik C., Porta C. et al. Renin angiotensin system deregulation as renal cancer risk factor.Oncol Lett. 2017; 14(5): 5059–5068. PMID: 29098020. DOI: 10.3892/ol.2017.6826</mixed-citation><mixed-citation xml:lang="ru">Sobczuk P., Szczylik C., Porta C. et al. Renin angiotensin system deregulation as renal cancer risk factor. Oncol Lett 2017; 14(5):5059–68. DOI: 10.3892/ol.2017.6826.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Errarte P1., Beitia M., Perez I. Expression and activity of angiotensin-regulating enzymes is associated with prognostic outcome in clear cell renal cell carcinoma patients. PLoS One. 2017;12(8):e0181711. PMID: 28809959. DOI: 10.1371/journal.pone.0181711.</mixed-citation><mixed-citation xml:lang="ru">Errarte P., Beitia M., Perez I. et al. Expression and activity of angiotensin-regulating enzymes is associated with prognostic outcome in clear cell renal cell carcinoma patients. PLoS One 2017;12(8):e0181711. DOI: 10.1371/journal.pone.0181711.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Larrinaga G., Pérez I., Sanz B. et al. Angiotensin-converting enzymes (ACE and ACE2) are downregulated in renal tumors. Regul Pept. 2010;165(2-3):218-23. PMID:20692300. DOI:10.1016/j.regpep.2010.07.17</mixed-citation><mixed-citation xml:lang="ru">Larrinaga G., Pérez I., Sanz B. et al. Angiotensin-converting enzymes (ACE and ACE2) are downregulated in renal tumors. Regul Pept 2010;165(2–3):218–23. DOI: 10.1016/j.regpep.2010.07.17.</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Gallagher P.E., Arter A.L., Deng G., Tallant E.A. Angiotensin-(1-7): a peptide hormone with anti-cancer activity. Curr Med Chem. 2014; 21(21):2417-23. PMID: 24524765. DOI: 10.2174/0929867321666140205133357</mixed-citation><mixed-citation xml:lang="ru">Gallagher P.E., Arter A.L., Deng G., Tallant E.A. Angiotensin-(1–7): a peptide hormone with anti-cancer activity. Curr Med Chem 2014;21(21):2417–23. DOI: 10.2174/0929867321666140205133357.</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Zheng S., Yang Y., Song R. et al. Ang-(1-7) promotes the migration and invasion of human renal cell carcinoma cells via Mas-mediated AKT signaling pathway. Biochem Biophys Res Commun. 2015; 460(2):333-40. PMID: 25783053. DOI: 10.1016/j.bbrc.2015.03.035</mixed-citation><mixed-citation xml:lang="ru">Zheng S., Yang Y., Song R. et al. Ang-(1–7) promotes the migration and invasion of human renal cell carcinoma cells via Masmediated AKT signaling pathway. Biochem Biophys Res Commun 2015;460(2):333–40. DOI: 10.1016/j.bbrc.2015.03.035.</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Beyazit Y., Purnak T., Suvak B. et al. Increased ACE in extrahepatic cholangiocarcinoma as a clue for activated RAS in biliary neoplasms. Clin Res Hepatol Gastroenterol 2011;35:644–9. PMID: 21802387. DOI: 10.1016/j.clinre.2011.06.008</mixed-citation><mixed-citation xml:lang="ru">Beyazit Y., Purnak T., Suvak B. et al. Increased ACE in extrahepatic cholangiocarcinoma as a clue for activated RAS in biliary neoplasms. Clin Res Hepatol Gastroenterol 2011;35(10):644–9. DOI: 10.1016/j.clinre.2011.06.008.</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">Herr D., Sauer C., Holzheu I. et al. Role of Renin-Angiotensin-System in Human Breast Cancer Cells: Is There a Difference in Regulation of Angiogenesis between Hormone-Receptor Positive and Negative Breast Cancer Cells? Geburtshilfe Frauenheilkd. 2019; 79(6):626-634. PMID: 19509262. DOI: 10.1158/1535-7163.MCT-09-0161</mixed-citation><mixed-citation xml:lang="ru">Herr D., Sauer C., Holzheu I. et al. Role of renin-angiotensin-system in human breast cancer cells: is there a difference in regulation of angiogenesis between hormone-receptor positive and negative breast cancer cells? Geburtshilfe Frauenheilkd 2019;79(6):626–34. DOI: 10.1158/1535-7163.MCT-09-0161.</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Bernardi S., Zennaro C., Palmisano S. et al. Characterization and significance of ACE2 and Mas receptor in human colon adenocarcinoma. J Renin Angiotensin Aldosterone Syst. 2012; 13(1):202-9. PMID: 22048948. DOI: 10.1177/1470320311426023</mixed-citation><mixed-citation xml:lang="ru">Bernardi S., Zennaro C., Palmisano S. et al. Characterization and significance of ACE2 and Mas receptor in human colon adenocarcinoma. J Renin Angiotensin Aldosterone Syst 2012;13(1):202–9. DOI: 10.1177/1470320311426023.</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">Yu C., Tang W., Wang Y. et al. Downregulation of ACE2/Ang-(1-7)/Mas axis promotes breast cancer metastasis by enhancing store-operated calcium entry. Cancer Lett. 2016; 376(2):268-77. PMID: 27063099. DOI: 10.1016/j.canlet.2016.04.006</mixed-citation><mixed-citation xml:lang="ru">Yu C., Tang W., Wang Y. et al. Downregulation of ACE2/Ang-(1-7)/Mas axis promotes breast cancer metastasis by enhancing store-operated calcium entry. Cancer Lett 2016;376(2):268–77. DOI: 10.1016/j.canlet.2016.04.006.</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">Xu J., Jinshuo F., Feng W. et al. The ACE2/Angiotensin-(1–7)/Mas Receptor Axis: Pleiotropic Roles in Cancer Front Physiol. 2017; 8: 276. PMID: 28533754. DOI: 10.3389/fphys.2017.00276</mixed-citation><mixed-citation xml:lang="ru">Xu J., Jinshuo F., Feng W. et al. The ACE2/ Angiotensin-(1–7)/Mas receptor axis: pleiotropic roles in cancer. Front Physiol 2017; 8:276. DOI: 10.3389/fphys.2017.00276.</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">Zimmerman D., Burns K.D. Angiotensin-(1-7) in kidney disease: a review of the controversies. Clin Sci (Lond). 2012 Sep;123(6):333-46. PMID: 22639821. DOI: 10.1042/CS20120111.</mixed-citation><mixed-citation xml:lang="ru">Zimmerman D., Burns K.D. Angiotensin-(1–7) in kidney disease: a review of the controversies. Clin Sci (Lond) 2012;123(6): 333–46. DOI: 10.1042/CS20120111.</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><mixed-citation>Giani J.F., Janjulia T., Taylor B. et al. Renal Generation of Angiotensin II and the Pathogenesis of Hypertension Curr Hypertens Rep. 2014 Sep; 16(9): 477. PMID: 25097114. DOI: 10.1007/s11906-014-0477-1</mixed-citation></ref></ref-list></back></article>
